Survodutide studies
136 journal papers mention Survodutide in the title or abstract. Here are the most cited, the latest, and a few facts about the literature.
Studies range from laboratory work to clinical trials. A paper listed here is not an endorsement and says nothing about whether Survodutide is safe, effective or approved for any use.
- Papers
- 136
- 85 articles, 51 reviews
- Earliest paper
- 2019
- Most papers in 2026 (53)
- Open access
- 68%
- free to read somewhere
- Reviews
- 38%
- of all papers listed
What kind of studies
Of 95 papers in PubMed that mention Survodutide in the title or abstract, by the study type PubMed records. Categories overlap, so they do not add up to the total.
- Randomized controlled trials10
- Other clinical trials2
- Meta-analyses and systematic reviews9
- Other reviews50
- Case reports0
- Animal studies only0
- Studies in humans59
Study types are tags assigned by publishers and PubMed indexers; very new papers are often not tagged yet, and a tag is not a quality rating. Retracted papers are excluded. Source: PubMed (NCBI).
Registered clinical studies
Studies on ClinicalTrials.gov that mention Survodutide in their intervention details. A registration says a study is planned or running, not what it found.
- Registered
- 36
- Completed
- 25
- Ongoing or planned
- 11
- Phase 1
- 20
- Phase 2
- 4
- Phase 3
- 12
- ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
NCT07850063Not yet recruitingPhase 3started 2026-11-02
- SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight
NCT07850050Not yet recruitingPhase 3started 2026-10-31
- A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
NCT07754461RecruitingPhase 3started 2026-08-24
- A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
NCT06077864CompletedPhase 3started 2023-11-20
- A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity
NCT07768813Active, not recruitingPhase 1started 2026-09-02
The five most recently updated studies. See all 36 on ClinicalTrials.gov. Source: ClinicalTrials.gov (U.S. National Library of Medicine). Studies are found by the compound's name, so a few may be about something else.
Papers per year
2019 to 2026, peak 53 papers in a year. The latest year may still be incomplete.
Where it is published
- Diabetes Obesity and Metabolism18 papers
- Diabetes15 papers
- Journal of the Endocrine Society4 papers
- Zeitschrift für Gastroenterologie3 papers
- Molecular Metabolism3 papers
The papers
Most citedName in the title
- Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials
Haijun Wan, Nuo Xu, Lijuan Wang et al. · Diabetology & Metabolic Syndrome · 2024
ReviewOpen access · CC BY-NC-ND8 citationsRead the open copy →
- Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction
Eda Kaya, Yusuf Yilmaz, Naim Alkhouri · Expert Opinion on Investigational Drugs · 2024
Review5 citations
- Efficacy and Safety of Twincretin Survodutide, a Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist as an Anti-Obesity and Anti-Diabetes Medication: A Systematic Review and Meta-Analysis
Deep Dutta, Abul B. M. Kamrul-Hasan, Ameya S Joshi et al. · Indian Journal of Endocrinology and Metabolism · 2025
ReviewOpen access · CC BY-NC-SA4 citationsRead the open copy →
- Evaluating the efficacy and safety of survodutide for obesity: a systematic review and meta-analysis of randomized controlled trials
Abdelaziz A. Awad, Alaa Abdrabou Abouelmagd, Fatma Mohammed et al. · Baylor University Medical Center Proceedings · 2025
ReviewOpen access3 citationsRead the open copy →
- A review of survodutide: a new dual acting agonist
Meenakshi Reddy Yathindra, Ayush BHATTACHARJEE, Nikhil PUNDIR et al. · Minerva Endocrinology · 2026
Review2 citations
- Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta‐analysis
Ya‐Jun Xiao, Shan Ping Yu, Yanling Zhang et al. · Diabetes Obesity and Metabolism · 2025
Meta-analysis2 citations
- Survodutide, a new horizon in the treatment of obesity and Type 2 diabetes mellitus: A narrative review
Abdelmoneim B. Yousif, Mohamed Fawzi Mudarres, Musaab Fahmi Yousef et al. · Yemen Journal of Medicine · 2024
ReviewOpen access · CC BY-NC-SA1 citationsRead the open copy →
LatestName in title or abstract
- EMERGING PHARMACOLOGICAL STRATEGIES IN OBESITY: FROM GLP-1 AGONISTS THROUGH TRIPLE INCRETIN THERAPY TO AMYLIN ANALOGS – NARRATIVE REVIEW
Dagmara Laufer, Olga Klimczak, Filip Chodań et al. · Archiv Euromedica · 2026
ReviewOpen accessRead the open copy →
- From pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease
Christiano Argano, Dalila Maggio, Chiara Pollicino et al. · Frontiers in Pharmacology · 2026
ReviewOpen access · CC BYRead the open copy →
- The Power of Two: Harnessing Dual Glucagon and Incretin Signaling for Treatment of Obesity and Metabolic Dysfunction–Associated Steatohepatitis—A Narrative Review with a Translational Focus
Jamy D. Ard, Jaime P. Almandoz · Obesity Reviews · 2026
ReviewOpen accessRead the open copy →
- Gastrointestinal adverse effects of GLP‐1 receptor agonists and dual GIP/GLP‐1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents
Fnu Vikash, Muhammad Ehsan, Sara Osorio Valencia et al. · Nutrition in Clinical Practice · 2026
ReviewOpen access · CC BY-NCRead the open copy →
- Efficacy and Safety of Dual GLP ‐1/Glucagon Receptor Agonism in Overweight and Obesity: A Class‐Specific Systematic Review and Meta‐Analysis
Muhammad Maaz Amjad, Muhammad Mustafa Khan, Fatima Sarwar et al. · Diabetes Obesity and Metabolism · 2026
ReviewOpen accessRead the open copy →
- Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review
Irma Melyani Puspitasari, Dimas Setyadi Putra, Alifa Nisa Deliyana et al. · Diabetes Metabolic Syndrome and Obesity · 2026
ReviewOpen access · CC BY-NCRead the open copy →
- MASLD: Established Knowledge and Emerging Directions – Guideline Updates
Elke Roeb, Andreas Geier · Zeitschrift für Gastroenterologie · 2026
Review
- Neue Therapieansätze bei MASH: Mechanismen und klinisches Potenzial
Alexander Barton, Jörn Markus Schattenberg · Zeitschrift für Gastroenterologie · 2026
Review
- Pathogenesis-Informed Phenotype-Guided Therapy for MASH: A Three-Axis Translational Framework Within the MASLD Spectrum
Zishu Zhao, Xiaoyang Hu · Biomedicines · 2026
ReviewOpen access · CC BYRead the open copy →
- Anti-Obesity Medications in Longevity and Aesthetic Medicine
Julia Bijoch · Journal of Clinical Medicine · 2026
ReviewOpen access · CC BYRead the open copy →
- Cardiovascular Effects of Glucagon Receptor Signaling Alone and Combined With Glucagon‐Like Peptide‐1 Receptor Signaling in Multiagonists: A Narrative Review With a Translational Focus
Pamela R. Kushner, Erin D. Michos · Journal of the American Heart Association · 2026
ReviewOpen access · CC BY1 citationsRead the open copy →
- Incretin analogues as cardiovascular agents: a state-of-the-art review
Diego Araiza Garaygordobil, Jorge E. Rico-Fontalvo, Betsabe Hernández-Balbuena et al. · Frontiers in Endocrinology · 2026
ReviewOpen access · CC BY1 citationsRead the open copy →
- Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis
Rogelio Santos Solís, Armando Baeza-Zapata, Juan Pablo Negrete‐Najar · Cureus · 2026
ReviewOpen access · CC BYRead the open copy →
Each list shows up to 40 papers.See all 136 on OpenAlex. Source: OpenAlex (CC0), journal articles and reviews with a DOI, retractions excluded, refreshed weekly, last 4 Nov 2026, 08:31 UTC. Papers are listed by their metadata only; follow the links to read them. A license shown on an open copy is the license the publisher or repository states for that copy.